Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aquinox Pharmaceuticals Inc.

Division of Neoleukin Therapeutics Inc.
www.aqxpharma.com

Latest From Aquinox Pharmaceuticals Inc.

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies

Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In

Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.

Financing Business Strategies

Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Aquinox, Astellas Mull Options As Rosiptor Fails

Astellas’ late-stage bet on Aquinox’s urology drug now looks highly unlikely to pay off following the molecule’s “definitive” failure in a Phase III trial, which is also forcing the originator to consider its business  and R&D options.

Commercial Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Neoleukin Therapeutics Inc.
  • Senior Management
  • Contact Info
  • Aquinox Pharmaceuticals Inc.
    Phone: (604) 629-9223
    887 Great Northern Way
    Ste. 450
    Vancouver, V5T 4T5
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register